Amazfit Expands HYROX Athlete Roster with Global Champions and Rising Stars
29.9.2025 18:00:00 CEST | Business Wire | Press Release
Amazfit, a leading global smart wearables brand by Zepp Health (NYSE: ZEPP), and the Official Timing & Wearable Partner of HYROX, today announced the expansion of its HYROX athlete roster, with Hunter McIntyre (USA) returning for another season and four standout competitors joining the team: Rich Ryan (USA), Joanna Wietrzyk (Australia), Emilie Dahmen (Netherlands), and Linda Meier (Germany).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250929662494/en/
Amazfit welcomes back Hunter McIntyre and expands its elite athlete team for the 2025/26 HYROX season with Rich Ryan, Joanna Wietrzyk, Emilie Dahmen, and Linda Meier
This roster reflects Amazfit’s commitment to supporting both proven champions and emerging talent in functional fitness racing, while integrating athlete feedback directly into product innovation.
Hunter McIntyre – Widely regarded as the face of HYROX, McIntyre remains one of the sport’s most dominant and influential athletes. A multiple-time champion with a loyal fanbase, he continues to push boundaries in competition and beyond, leading training camps and outdoor adventure races. McIntyre has been instrumental in Amazfit product development, relying on the rugged Amazfit T-Rex series to fuel his relentless pursuit of podium finishes.
"I'm excited to be returning to Team Amazfit for another few years. The products are great, they listen to me when I have input, and I feel like I am getting actionable insights that are helping to drive my training. We almost got it done last year in Chicago — this year I'm here for the gold."
-Hunter McIntyre
Rich Ryan – Known for his data-driven approach and coaching influence, Ryan brings dual impact as an elite competitor and educator. One of the fastest men on the HYROX course, he pairs his athlete achievements with seminars and coaching through his RMR training company. Ryan’s deep demand for precision aligns seamlessly with Amazfit’s Balance 2 and Helio series, making him a trusted partner in advancing performance metrics for athletes everywhere.
“I joined Team Amazfit because of their commitment to HYROX and hybrid training. I believe hybrid training and competition can help athletes grow into healthier, more effective versions of themselves, and having partners who share those values is really important to me. I’m also excited to collaborate with the team at Amazfit, who continue to push innovation and show real ambition in this space.”
-Rich Ryan
Joanna Wietrzyk – A breakout star from Australia, Wietrzyk stunned the HYROX community with a second-place finish in Chicago. A former competitive tennis player, she is quickly emerging as a top contender across solo and doubles formats. Wietrzyk, who will be sporting the Amazfit T-Rex 3, values her close collaboration with Amazfit’s sports marketing team and is poised to elevate both her career and the brand’s visibility globally.
“After an incredible first season in HYROX, I’m focused on building momentum and pushing my performance even further this year. That means going beyond what I’ve done before and partnering with teams that truly support the way I train, recover, and compete. Amazfit does exactly that. Their technology helps me stay consistent and intentional, whether I’m tracking key metrics during intense sessions or monitoring recovery post-race. Amazfit gives me the right tools to train smarter, stay balanced and continue progressing - and that’s what makes this partnership so exciting."
-Joanna Wietrzyk
Emilie Dahmen – One of the sport’s most exciting rising stars, Dahmen captured attention by winning two HYROX races in her debut season and finishing sixth at the World Championships. Still early in her career, she represents the next generation of HYROX talent. Dahmen’s embrace of Amazfit wearables, specifically the Balance 2 and Helio Strap, makes her a natural fit for the team as she continues her rapid ascent.
"I hadn’t relied on a watch or performance data before, and reaching the HYROX Elite 15 without it was already a huge achievement. Partnering with Amazfit now gives me the tools to train smarter, recover better, and truly compete at the highest level. Their technology helps me unlock even more potential, and I hope to inspire others to see how powerful smart training can be."
-Emilie Dahmen
Linda Meier – The reigning HYROX World Champion, Meier delivered a career-defining performance in Chicago to secure her title. Already a respected competitor, her consistency and professionalism make her an invaluable ambassador. Meier relies on the Amazfit Helio Strap and the Amazfit T-Rex 3 for advanced data insights, helping her balance performance and recovery at the highest level.
"With Amazfit by my side, I can combine my World Champion spirit with smart technology - showing that anyone can push beyond their limits with the right tools."
-Linda Meier
“Our partnership with HYROX is about helping athletes maximize every moment of training, performance, and recovery,” said Scott Shepley, Head of Global Marketing of Amazfit. “By signing a roster that blends world champions with promising new talent, we’re reinforcing Amazfit’s role as the performance partner of choice for athletes who trust data to fuel their goals.”
As part of Team Amazfit, these athletes will contribute to product testing, content storytelling, and community engagement, ensuring Amazfit continues to deliver cutting-edge tools that meet the evolving demands of functional fitness athletes.
Athletes and fans can explore Amazfit’s full range of smart wearables — including the T-Rex series, Balance 2, Active 2, and Helio Strap — at www.amazfit.com, and follow the brand’s HYROX journey throughout the 2025/26 season.
About Amazfit
Amazfit, a leading global smart wearable brand focused on health and fitness, is part of Zepp Health (NYSE: ZEPP), a health technology company with its principal office based in Gorinchem, the Netherlands. Zepp Health operates as a distributed organization, with team members and offices across the Americas, Europe, Asia, and other global markets.
Offering a wide selection of smartwatches and bands, Amazfit's brand tagline, “Discover Amazing,” encourages individuals to break barriers, exceed expectations, and find joy in every moment. Amazfit is powered by Zepp Health’s proprietary health management platform, which delivers cloud-based, 24/7 actionable insights and guidance to help users achieve their wellness goals.
Known for outstanding craftsmanship, Amazfit smartwatches have won numerous design awards, including the iF Design Award and the Red Dot Design Award. Launched in 2015, Amazfit is embraced by millions of users, with products available in over 90 countries across the Americas, EMEA, and APAC regions. For more information, visit www.amazfit.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250929662494/en/
Contacts
Media Contacts
Max Borges Agency for Amazfit
amazfit@maxborgesagency.com
Mary Thompson Woodbury
Head of PR, Amazfit North America
Mary.woodbury@zepp.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom